Virpax Pharmaceuticals, Inc. VRPX
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -97.30%
- 1 year
- -98.57%
- Market cap
- 372
- EPS (ttm)
- -1.92
- Shares out
- 8.09M
- Forward P/E
- -0.38
- YTD return
- -97.30%
- 1-year return
- -98.57%
- Volume
- 51
- Avg volume
- 323
- Open
- 0.021
- Previous close
- 0.0003
- Day's range
- 0.021 – 0.021
- 52-week range
- 0.0001 – 0.10
- Beta
- 1.09
- Price target
- 3.00 (+999900.0%)
2Y -17.2997 (-100.00%)
Key statistics
- Enterprise value
- 1.13M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.98M
- Total cash
- 1.87M
- Total debt
- 0
- Return on equity
- -362.29%
- Short % of float
- 7.65%
- 50-day average
- 0.54406
- 200-day average
- 1.40
Analyst view
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.43 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -1.75 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -2.75 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -5.10 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -2.70 | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | -1.30 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2024 | Maxim Group | down | Buy | Hold |
| Jul 19, 2024 | Maxim Group | up | Hold | Buy |
| May 22, 2024 | Maxim Group | down | Buy | Hold |
About Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- virpaxpharma.com
News
Reviewing Virpax Pharmaceuticals (NASDAQ:VRPX) and Zomedica (OTCMKTS:ZOMDF) 
Financial Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) versus Merck KGaA (OTCMKTS:MKGAF) 
Nabriva Therapeutics (NASDAQ:NBRV) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast 
12 Health Care Stocks Moving In Thursday's After-Market Session 
11 Health Care Stocks Moving In Thursday's Intraday Session 
US Stocks Likely To Open Lower After Fed Decision: Any Pullback In Equities 'Offers An Opportunity,' Says Expert 
Virpax Pharmaceuticals Announces Reverse Stock Split - 12 Health Care Stocks Moving In Tuesday's After-Market Session
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND 
12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on VRPX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.39% | 31,382 | 10.79K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 27,971 | 9.62K | Sep 29, 2024 |
| UBS Group AG | 0.25% | 20,435 | 7.03K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.15% | 12,522 | 4.31K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 3,837 | 1.32K | Sep 29, 2024 |
| Signature Resources Capital Management, LLC | 0.00% | 50 | 17 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.31% | 25,474 | 8.76K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 8,756 | 3.01K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 6,629 | 2.28K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 6,857 | 2.36K | Oct 30, 2024 |